Association between white matter impairment and cognitive dysfunction in patients with ischemic Moyamoya disease

• Main Authors: Ziqi Liu, Shihao He, Zongsheng Xu, Ran Duan, Li Yuan, Chu Xiao, Zhe Yi, Rong Wang
• Format: Article
• Language: English
• Published: BMC 2020-08-01
• Series: BMC Neurology
• Subjects: Moyamoya disease; Cognitive dysfunction; Diffusion tensor imaging; Tract-based spatial statistics; Ischemic cerebrovascular disease
• Online Access: http://link.springer.com/article/10.1186/s12883-020-01876-0

Abstract Background Ischemic Moyamoya disease is one of the important causes of stroke, which leads to severe impairment in cognitive functions. This cognitive impairment occurs prior to stroke. However, the cognitive functions that are impaired and the mechanisms of these impairments have not been determined. Methods We analyzed 12 patients with Moyamoya disease and 12 controls. All participants underwent cognitive tests and magnetic resonance imaging (MRI) scans. The diffusion tensor imaging (DTI) data was processed using Tract-Based Spatial Statistics (TBSS). Significantly different white matter areas were correlated with different cognitive functions. Results There were significant differences in intelligence and subtraction between the patients and controls (p < 0.05). The parameters of DTI such as fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) have different changes in anterior thalamic radiation, inferior fronto-occipital fasciculus (IFO), superior longitudinal fasciculus (SLF), uncinate fasciculus (UF), inferior longitudinal fasciculus, forceps minor, and other regions between the two groups. Conclusion Left UF and IFO may be the key brain regions affecting arithmetic function, while bilateral IFO has an effect on intelligence. RD and AD may be better indicators for early prediction of chronic white matter damage than FA, while MD tends to have a comprehensive indirect change. There is cognitive impairment in ischemic MMD, which is closely related to white matter impairment. Trial registration Clinical Trial Registration, Unique identifier: ChiCTR1900023610 . Registered 4 June 2019 – Prospective study registered.